Compare AdaptHealth Corp (AHCO) vs Stryker Corporation (SYK) Price & Performance

AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.

The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.

Stryker (SYK) trades at $324.73, down 0.55% on the day, with a bullish technical outlook supported by moving averages. The company maintains strong fundamentals with 2025 revenue of $25.12B, net income of $3.25B, and consistent earnings beats in recent quarters despite a Q1 2026 miss. Analyst consensus remains strongly positive with 72% buy ratings and a $385.30 price target, representing 19% upside potential. Recent developments include new product launches and a strategic acquisition of Amplitude Vascular Systems.

SYK presents a compelling investment case with robust profitability (63.83% gross margin, 15.2% ROE) and strong institutional support. Key risks include cybersecurity incidents impacting operations and premium valuation metrics (P/E 37.58). The stock's current position near pivot point support at $323 suggests potential for recovery toward resistance at $329, supported by positive technical indicators and strong analyst conviction.